{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560042,"version":"build-2803163510"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00223-020-00705-3","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T18:03:06Z","timestamp":1591380186000},"page":"143-157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["New Therapies for Hypophosphatemia-Related to FGF23 Excess"],"prefix":"10.1007","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-5248","authenticated-orcid":false,"given":"Diana","family":"Athonvarangkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl L.","family":"Insogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"issue":"3","key":"705_CR1","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1530\/ERC-11-0006","volume":"18","author":"WH Chong","year":"2011","unstructured":"Chong WH et al (2011) Tumor-induced osteomalacia. Endocr Relat Cancer 18(3):R53\u2013R77","journal-title":"Endocr Relat Cancer"},{"key":"705_CR2","doi-asserted-by":"publisher","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S et al (2017) Tumour-induced osteomalacia. Nature reviews Disease primers 3:17044\u201317044","journal-title":"Nature reviews Disease primers"},{"issue":"18","key":"705_CR3","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJM198010303031802","volume":"303","author":"FH Glorieux","year":"1980","unstructured":"Glorieux FH et al (1980) Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med 303(18):1023\u20131031","journal-title":"N Engl J Med"},{"issue":"21","key":"705_CR4","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa1714641","volume":"378","author":"TO Carpenter","year":"2018","unstructured":"Carpenter TO et al (2018) Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med 378(21):1987\u20131998","journal-title":"N Engl J Med"},{"issue":"10189","key":"705_CR5","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/S0140-6736(19)30654-3","volume":"393","author":"EA Imel","year":"2019","unstructured":"Imel EA et al (2019) Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet 393(10189):2416\u20132427","journal-title":"Lancet"},{"issue":"7","key":"705_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA et al (2015) Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. The Journal of clinical endocrinology and metabolism 100(7):2565\u20132573","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"8","key":"705_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/jbmr.3475","volume":"33","author":"KL Insogna","year":"2018","unstructured":"Insogna KL et al (2018) A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res 33(8):1383\u20131393","journal-title":"J Bone Miner Res"},{"issue":"12","key":"705_CR8","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/jbmr.3843","volume":"34","author":"KL Insogna","year":"2019","unstructured":"Insogna KL et al (2019) Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm. International Trial J Bone Miner Res 34(12):2183\u20132191","journal-title":"International Trial J Bone Miner Res"},{"issue":"3","key":"705_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00223-019-00568-3","volume":"105","author":"AA Portale","year":"2019","unstructured":"Portale AA et al (2019) Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. Calcif Tissue Int 105(3):271\u2013284","journal-title":"Calcif Tissue Int"},{"key":"705_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone reports 5:158\u2013162","journal-title":"Bone reports"},{"key":"705_CR11","doi-asserted-by":"crossref","unstructured":"Jan de Beur, S., et al., Burosumab improves the biochemical, skeletal, and clinical symptoms of tumor-induced osteomalacia (TIO) syndrome, in World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases. 2019: Paris, France.","DOI":"10.1210\/js.2019-OR13-1"},{"issue":"12","key":"705_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.tem.2012.07.002","volume":"23","author":"N Bhattacharyya","year":"2012","unstructured":"Bhattacharyya N et al (2012) Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol Metab 23(12):610\u2013618","journal-title":"Trends Endocrinol Metab"},{"issue":"15","key":"705_CR13","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1073\/pnas.1402218111","volume":"111","author":"VS Tagliabracci","year":"2014","unstructured":"Tagliabracci VS et al (2014) Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A 111(15):5520\u20135525","journal-title":"Proc Natl Acad Sci U S A"},{"key":"705_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.mce.2016.05.008","volume":"432","author":"RG Erben","year":"2016","unstructured":"Erben RG (2016) Update on FGF23 and Klotho signaling. Mol Cell Endocrinol 432:56\u201365","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"705_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.bone.2012.05.015","volume":"51","author":"O Andrukhova","year":"2012","unstructured":"Andrukhova O et al (2012) FGF23 acts directly on renal proximal tubules to induce phosphaturia through activation of the ERK1\/2-SGK1 signaling pathway. Bone 51(3):621\u2013628","journal-title":"Bone"},{"issue":"4","key":"705_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T et al (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113(4):561\u2013568","journal-title":"J Clin Invest"},{"issue":"3","key":"705_CR17","first-page":"529","volume":"54","author":"F Albright","year":"1937","unstructured":"Albright F, Butler AM, Bloomberg E (1937) RICKETS RESISTANT TO VITAMIN D THERAPY. Am J Dis Child 54(3):529\u2013547","journal-title":"Am J Dis Child"},{"issue":"12","key":"705_CR18","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.1073\/pnas.73.12.4667","volume":"73","author":"EM Eicher","year":"1976","unstructured":"Eicher EM et al (1976) Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 73(12):4667\u20134671","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"705_CR19","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/archinte.1974.00320210159025","volume":"134","author":"JM Morgan","year":"1974","unstructured":"Morgan JM et al (1974) Renal transplantation in hypophosphatemia with vitamin D-resistant rickets. Arch Intern Med 134(3):549\u2013552","journal-title":"Arch Intern Med"},{"issue":"4","key":"705_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/jbmr.5650040407","volume":"4","author":"RA Meyer Jr","year":"1989","unstructured":"Meyer RA Jr, Meyer MH, Gray RW (1989) Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4(4):493\u2013500","journal-title":"J Bone Miner Res"},{"issue":"2","key":"705_CR21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/ng1095-130","volume":"11","author":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets","year":"1995","unstructured":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets (1995) The HYP Consortium. Nat Genet 11(2):130\u2013136","journal-title":"Nat Genet"},{"issue":"3","key":"705_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/81664","volume":"26","author":"KE White","year":"2000","unstructured":"White KE, Evans WE (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26(3):345\u2013348","journal-title":"Nat Genet"},{"issue":"11","key":"705_CR23","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1073\/pnas.101545198","volume":"98","author":"T Shimada","year":"2001","unstructured":"Shimada T et al (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98(11):6500\u20136505","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"705_CR24","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1056\/NEJMoa020881","volume":"348","author":"KB Jonsson","year":"2003","unstructured":"Jonsson KB et al (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348(17):1656\u20131663","journal-title":"N Engl J Med"},{"issue":"11","key":"705_CR25","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.1210\/jc.2002-021105","volume":"87","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y et al (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia. J Clin Endocrinol Metab 87(11):4957\u20134960","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"705_CR26","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1359\/jbmr.090832","volume":"25","author":"WN Addison","year":"2010","unstructured":"Addison WN et al (2010) Phosphorylation-dependent inhibition of mineralization by osteopontin ASARM peptides is regulated by PHEX cleavage. J Bone Miner Res 25(4):695\u2013705","journal-title":"J Bone Miner Res"},{"issue":"3","key":"705_CR27","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/jbmr.1766","volume":"28","author":"NM Barros","year":"2013","unstructured":"Barros NM et al (2013) Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res 28(3):688\u2013699","journal-title":"J Bone Miner Res"},{"issue":"3","key":"705_CR28","doi-asserted-by":"publisher","first-page":"F783","DOI":"10.1152\/ajprenal.00304.2010","volume":"300","author":"V David","year":"2011","unstructured":"David V et al (2011) ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol 300(3):F783\u2013F791","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"705_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS et al (2009) Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol 160(3):491\u2013497","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"705_CR30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1530\/EJE-15-0515","volume":"174","author":"S Rafaelsen","year":"2016","unstructured":"Rafaelsen S et al (2016) Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur J Endocrinol 174(2):125\u2013136","journal-title":"Eur J Endocrinol"},{"key":"705_CR31","unstructured":"Ruppe, M.D., X-Linked Hypophosphatemia, in GeneReviews (Internet), M.P. Adam, et al., Editors. 1993, University of Washington, Seattle; 1993\u20132019.: Seattle (WA)."},{"issue":"3","key":"705_CR32","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jbmr.3614","volume":"34","author":"A Rothenbuhler","year":"2019","unstructured":"Rothenbuhler A et al (2019) High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR). J Bone Miner Res 34(3):490\u2013496","journal-title":"J Bone Miner Res"},{"issue":"2","key":"705_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.bone.2009.09.016","volume":"46","author":"S Turan","year":"2010","unstructured":"Turan S et al (2010) Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone 46(2):402\u2013409","journal-title":"Bone"},{"issue":"10","key":"705_CR34","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1096\/fj.201600473R","volume":"30","author":"DH Pesta","year":"2016","unstructured":"Pesta DH et al (2016) Hypophosphatemia promotes lower rates of muscle ATP synthesis. Faseb j 30(10):3378\u20133387","journal-title":"Faseb j"},{"issue":"10","key":"705_CR35","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1210\/JC.2015-2199","volume":"100","author":"J Connor","year":"2015","unstructured":"Connor J et al (2015) Conventional Therapy in Adults With X-Linked Hypophosphatemia: Effects on Enthesopathy and Dental Disease. J Clin Endocrinol Metab 100(10):3625\u20133632","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"705_CR36","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","volume":"85","author":"G Liang","year":"2009","unstructured":"Liang G et al (2009) Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice. Calcif Tissue Int 85(3):235\u2013246","journal-title":"Calcif Tissue Int"},{"key":"705_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ijscr.2016.08.038","volume":"27","author":"Y Hirao","year":"2016","unstructured":"Hirao Y et al (2016) Extensive ossification of the paraspinal ligaments in a patient with vitamin D-resistant rickets: Case report with literature review. Int J Surg Case Rep 27:125\u2013128","journal-title":"Int J Surg Case Rep"},{"issue":"1","key":"705_CR38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4184\/asj.2015.9.1.106","volume":"9","author":"M Shiba","year":"2015","unstructured":"Shiba M et al (2015) Cervical ossification of posterior longitudinal ligament in x-linked hypophosphatemic rickets revealing homogeneously increased vertebral bone density. Asian Spine J 9(1):106\u2013109","journal-title":"Asian Spine J"},{"issue":"5","key":"705_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s10545-018-0147-6","volume":"41","author":"D Chesher","year":"2018","unstructured":"Chesher D et al (2018) Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis 41(5):865\u2013876","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"705_CR40","first-page":"622","volume":"163","author":"G Fishman","year":"2004","unstructured":"Fishman G et al (2004) Hearing impairment in familial X-linked hypophosphatemic rickets. Eur J Pediatr 163(10):622\u2013623","journal-title":"Eur J Pediatr"},{"issue":"7","key":"705_CR41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO et al (2011) A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res 26(7):1381\u20131388","journal-title":"J Bone Miner Res"},{"issue":"6","key":"705_CR42","first-page":"1378","volume":"78","author":"TO Carpenter","year":"1994","unstructured":"Carpenter TO et al (1994) Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78(6):1378\u20131383","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"705_CR43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1067\/mpd.2001.108955","volume":"138","author":"GI Baroncelli","year":"2001","unstructured":"Baroncelli GI et al (2001) Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. J Pediatr 138(2):236\u2013243","journal-title":"J Pediatr"},{"issue":"6","key":"705_CR44","doi-asserted-by":"publisher","first-page":"e593","DOI":"10.1542\/peds.113.6.e593","volume":"113","author":"D Haffner","year":"2004","unstructured":"Haffner D et al (2004) Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. Pediatrics 113(6):e593\u2013e596","journal-title":"Pediatrics"},{"issue":"12","key":"705_CR45","doi-asserted-by":"publisher","first-page":"E2097","DOI":"10.1210\/jc.2011-0399","volume":"96","author":"M Zivicnjak","year":"2011","unstructured":"Zivicnjak M et al (2011) Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J Clin Endocrinol Metab 96(12):E2097\u2013E2105","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"705_CR46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1542\/peds.75.4.754","volume":"75","author":"U Alon","year":"1985","unstructured":"Alon U, Chan JC (1985) Effects of hydrochlorothiazide and amiloride in renal hypophosphatemic rickets. Pediatrics 75(4):754\u2013763","journal-title":"Pediatrics"},{"issue":"1","key":"705_CR47","doi-asserted-by":"publisher","first-page":"E6","DOI":"10.1542\/peds.108.1.e6","volume":"108","author":"MG Seikaly","year":"2001","unstructured":"Seikaly MG, Baum M (2001) Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics 108(1):E6","journal-title":"Pediatrics"},{"issue":"6","key":"705_CR48","first-page":"2381","volume":"81","author":"TO Carpenter","year":"1996","unstructured":"Carpenter TO et al (1996) 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and improves skeletal abnormalities in X-linked hypophosphatemic rickets\u2013a clinical research center study. J Clin Endocrinol Metab 81(6):2381\u20132388","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"705_CR49","first-page":"879","volume":"75","author":"W Sullivan","year":"1992","unstructured":"Sullivan W et al (1992) A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 75(3):879\u2013885","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"705_CR50","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1210\/jc.2014-2017","volume":"99","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO et al (2014) Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 99(9):3103\u20133111","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"705_CR51","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA et al (2015) Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocrinol Metab 100(7):2565\u20132573","journal-title":"J Clin Endocrinol Metab"},{"key":"705_CR52","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","volume":"5","author":"MD Ruppe","year":"2016","unstructured":"Ruppe MD et al (2016) Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia. Bone Rep 5:158\u2013162","journal-title":"Bone Rep"},{"issue":"2","key":"705_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.bone.2004.04.002","volume":"35","author":"A Benet-Pages","year":"2004","unstructured":"Benet-Pages A et al (2004) FGF23 is processed by proprotein convertases but not by PHEX. Bone 35(2):455\u2013462","journal-title":"Bone"},{"issue":"2","key":"705_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jcem.82.2.3765","volume":"82","author":"MJ Econs","year":"1997","unstructured":"Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets\/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82(2):674\u2013681","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"705_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","volume":"23","author":"M Wolf","year":"2014","unstructured":"Wolf M, White KE (2014) Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens 23(4):411\u2013419","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"705_CR56","doi-asserted-by":"crossref","unstructured":"Imel, E.A., et al., Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets. J Bone Miner Res, 2019.","DOI":"10.1002\/jbmr.3878"},{"issue":"7\u20138","key":"705_CR57","first-page":"967","volume":"28","author":"E Steichen-Gersdorf","year":"2015","unstructured":"Steichen-Gersdorf E et al (2015) Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1. J Pediatr Endocrinol Metab 28(7\u20138):967\u2013970","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"11","key":"705_CR58","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ng1905","volume":"38","author":"JQ Feng","year":"2006","unstructured":"Feng JQ et al (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38(11):1310\u20131315","journal-title":"Nat Genet"},{"issue":"3","key":"705_CR59","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1210\/en.2016-1642","volume":"158","author":"S Ichikawa","year":"2017","unstructured":"Ichikawa S et al (2017) A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice. Endocrinology 158(3):470\u2013476","journal-title":"Endocrinology"},{"issue":"1","key":"705_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200401000-00001","volume":"28","author":"AL Folpe","year":"2004","unstructured":"Folpe AL et al (2004) Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28(1):1\u201330","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"705_CR61","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1210\/jc.2004-0357","volume":"90","author":"TO Carpenter","year":"2005","unstructured":"Carpenter TO et al (2005) Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90(2):1012\u20131020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"705_CR62","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","volume":"17","author":"SM De Beur","year":"2002","unstructured":"De Beur SM et al (2002) Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 17(6):1102\u20131110","journal-title":"J Bone Miner Res"},{"key":"705_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bonr.2017.09.002","volume":"7","author":"P Florenzano","year":"2017","unstructured":"Florenzano P, Gafni RI, Collins MT (2017) Tumor-induced osteomalacia Bone reports 7:90\u201397","journal-title":"Tumor-induced osteomalacia Bone reports"},{"issue":"1","key":"705_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000282746","volume":"55","author":"H Nakahama","year":"1995","unstructured":"Nakahama H et al (1995) Prostate cancer-induced oncogenic hypophosphatemic osteomalacia. Urol Int 55(1):38\u201340","journal-title":"Urol Int"},{"issue":"5","key":"705_CR65","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jbspin.2004.10.012","volume":"72","author":"J Narvaez","year":"2005","unstructured":"Narvaez J et al (2005) Acquired hypophosphatemic osteomalacia associated with multiple myeloma. Joint Bone Spine 72(5):424\u2013426","journal-title":"Joint Bone Spine"},{"key":"705_CR66","unstructured":"Sanders, L., The young woman was a healthy and avid runner. Now she could barely walk. Why?, in The New York Times. 2018: New York, NY. p. 20."},{"key":"705_CR67","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1210\/js.2019-OR13-1","volume":"2019","author":"S Jan De Beur","year":"2019","unstructured":"Jan De Beur S et al (2019) OR13\u20131 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome. Journal of the Endocrine Society 2019:2019. https:\/\/doi.org\/10.1210\/js.2019-OR13-1","journal-title":"Journal of the Endocrine Society"},{"issue":"4","key":"705_CR68","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/path.4465","volume":"235","author":"JC Lee","year":"2015","unstructured":"Lee JC et al (2015) Identification of a novel FN1-FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J Pathol 235(4):539\u2013545","journal-title":"J Pathol"},{"issue":"10","key":"705_CR69","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1210\/jc.2016-2052","volume":"101","author":"D El-Maouche","year":"2016","unstructured":"El-Maouche D et al (2016) (68)Ga-DOTATATE for Tumor Localization in Tumor-Induced Osteomalacia. The Journal of clinical endocrinology and metabolism 101(10):3575\u20133581","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"9308","key":"705_CR70","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM Jan de Beur","year":"2002","unstructured":"Jan de Beur SM et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761\u2013763","journal-title":"Lancet"},{"issue":"1","key":"705_CR71","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1359\/jbmr.060909","volume":"22","author":"E Hesse","year":"2007","unstructured":"Hesse E et al (2007) Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 22(1):158\u2013162","journal-title":"J Bone Miner Res"},{"issue":"4","key":"705_CR72","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMc070347","volume":"357","author":"E Hesse","year":"2007","unstructured":"Hesse E, Rosenthal H, Bastian L (2007) Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 357(4):422\u2013424","journal-title":"N Engl J Med"},{"issue":"6","key":"705_CR73","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s00259-004-1697-4","volume":"32","author":"D Wild","year":"2005","unstructured":"Wild D et al (2005) 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging 32(6):724","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"705_CR74","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/RLU.0000000000000854","volume":"40","author":"J Zhang","year":"2015","unstructured":"Zhang J et al (2015) 68Ga DOTATATE PET\/CT is an Accurate Imaging Modality in the Detection of Culprit Tumors Causing Osteomalacia. Clin Nucl Med 40(8):642\u2013646","journal-title":"Clin Nucl Med"},{"issue":"1","key":"705_CR75","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/cen.12822","volume":"84","author":"N Bhavani","year":"2016","unstructured":"Bhavani N et al (2016) Utility of Gallium-68 DOTANOC PET\/CT in the localization of Tumour-induced osteomalacia. Clin Endocrinol 84(1):134\u2013140","journal-title":"Clin Endocrinol"},{"key":"705_CR76","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","volume":"56","author":"SJ Rayamajhi","year":"2019","unstructured":"Rayamajhi SJ et al (2019) Tumor-induced osteomalacia - Current imaging modalities and a systematic approach for tumor localization. Clin Imaging 56:114\u2013123","journal-title":"Clin Imaging"},{"issue":"9","key":"705_CR77","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1007\/s00270-016-1350-1","volume":"39","author":"M Maybody","year":"2016","unstructured":"Maybody M et al (2016) Ga-68 DOTATOC PET\/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia. Cardiovasc Intervent Radiol 39(9):1352\u20131357","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"705_CR78","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2967\/jnmt.116.177873","volume":"44","author":"S Basu","year":"2016","unstructured":"Basu S, Fargose P (2016) 177Lu-DOTATATE PRRT in Recurrent Skull-Base Phosphaturic Mesenchymal Tumor Causing Osteomalacia: A Potential Application of PRRT Beyond Neuroendocrine Tumors. Journal of nuclear medicine technology 44(4):248\u2013250","journal-title":"Journal of nuclear medicine technology"},{"issue":"12","key":"705_CR79","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1210\/jc.2011-1757","volume":"96","author":"WH Chong","year":"2011","unstructured":"Chong WH et al (2011) The importance of whole body imaging in tumor-induced osteomalacia. The Journal of clinical endocrinology and metabolism 96(12):3599\u20133600","journal-title":"The Journal of clinical endocrinology and metabolism"},{"key":"705_CR80","unstructured":"Collins, M.T., et al., Striking Response of Tumor-Induced Osteomalacia to the FGFR Inhibitor NVP-BGJ398. J Bone Miner Res, 2015. 28(Supplement 1): p. Available at https:\/\/www.asbmr.org\/education\/AbstractDetail?aid=c5464be6-d873-49f3-bb71-719e2198867e. Accessed January 8, 2020."},{"issue":"11","key":"705_CR81","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrneph.2015.153","volume":"11","author":"LC Baia","year":"2015","unstructured":"Baia LC et al (2015) Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol 11(11):656\u2013666","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"705_CR82","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2169\/naika.71.1566","volume":"71","author":"M Okada","year":"1982","unstructured":"Okada M et al (1982) 2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide. Nihon Naika Gakkai Zasshi 71(11):1566\u20131572","journal-title":"Nihon Naika Gakkai Zasshi"},{"issue":"2","key":"705_CR83","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/BF01496662","volume":"61","author":"M Okada","year":"1983","unstructured":"Okada M et al (1983) Hypophosphatemia induced by intravenous administration of Saccharated iron oxide. Klin Wochenschr 61(2):99\u2013102","journal-title":"Klin Wochenschr"},{"issue":"1","key":"705_CR84","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S8756-3282(97)00084-7","volume":"21","author":"K Sato","year":"1997","unstructured":"Sato K et al (1997) Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules. Bone 21(1):57\u201364","journal-title":"Bone"},{"issue":"4","key":"705_CR85","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1507\/endocrj.45.431","volume":"45","author":"K Sato","year":"1998","unstructured":"Sato K, Shiraki M (1998) Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy. Endocr J 45(4):431\u2013439","journal-title":"Endocr J"},{"issue":"Pt 2","key":"705_CR86","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1258\/acb.2008.008151","volume":"46","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ et al (2009) Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 46(Pt 2):167\u2013169","journal-title":"Ann Clin Biochem"},{"issue":"17","key":"705_CR87","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.2169\/internalmedicine.51.7450","volume":"51","author":"S Yamamoto","year":"2012","unstructured":"Yamamoto S et al (2012) Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. Intern Med 51(17):2375\u20132378","journal-title":"Intern Med"},{"issue":"6","key":"705_CR88","first-page":"316","volume":"75","author":"K Imamura","year":"1984","unstructured":"Imamura K (1984) Effects of intravenous administration of iron preparations on the metabolism of phosphorus Comparative study on 3 iron preparations. Fukuoka Igaku Zasshi 75(6):316\u2013326","journal-title":"Fukuoka Igaku Zasshi"},{"issue":"12","key":"705_CR89","doi-asserted-by":"publisher","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","volume":"11","author":"B Schaefer","year":"2016","unstructured":"Schaefer B et al (2016) Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk. PLoS ONE 11(12):e0167146","journal-title":"PLoS ONE"},{"issue":"5\u20136","key":"705_CR90","first-page":"333","volume":"12","author":"AJ Felsenfeld","year":"1986","unstructured":"Felsenfeld AJ et al (1986) Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25-dihydroxycholecalciferol. Miner Electrolyte Metab 12(5\u20136):333\u2013341","journal-title":"Miner Electrolyte Metab"},{"issue":"6","key":"705_CR91","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1046\/j.1523-1755.2001.00755.x","volume":"59","author":"M Levi","year":"2001","unstructured":"Levi M (2001) Post-transplant hypophosphatemia. Kidney Int 59(6):2377\u20132387","journal-title":"Kidney Int"},{"issue":"7860","key":"705_CR92","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S0140-6736(74)92902-X","volume":"1","author":"JF Moorhead","year":"1974","unstructured":"Moorhead JF et al (1974) Hypophosphataemic osteomalacia after cadaveric renal transplantation. Lancet 1(7860):694\u2013697","journal-title":"Lancet"},{"issue":"4","key":"705_CR93","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/ki.1981.54","volume":"19","author":"RW Rosenbaum","year":"1981","unstructured":"Rosenbaum RW et al (1981) Decreased phosphate reabsorption after renal transplantation: Evidence for a mechanism independent of calcium and parathyroid hormone. Kidney Int 19(4):568\u2013578","journal-title":"Kidney Int"},{"issue":"5","key":"705_CR94","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1600-6143.2007.01753.x","volume":"7","author":"P Evenepoel","year":"2007","unstructured":"Evenepoel P et al (2007) Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 7(5):1193\u20131200","journal-title":"Am J Transplant"},{"issue":"5","key":"705_CR95","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ckj\/sfw072","volume":"9","author":"G Cianciolo","year":"2016","unstructured":"Cianciolo G, Cozzolino M (2016) FGF23 in kidney transplant: the strange case of Doctor Jekyll and Mister Hyde. Clin Kidney J 9(5):665\u2013668","journal-title":"Clin Kidney J"},{"issue":"2","key":"705_CR96","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1053\/j.ajkd.2012.07.022","volume":"61","author":"HM Alshayeb","year":"2013","unstructured":"Alshayeb HM, Josephson MA, Sprague SM (2013) CKD-mineral and bone disorder management in kidney transplant recipients. Am J Kidney Dis 61(2):310\u2013325","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"705_CR97","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1159\/000446863","volume":"43","author":"G Cianciolo","year":"2016","unstructured":"Cianciolo G et al (2016) Vitamin D in Kidney Transplant Recipients: Mechanisms and Therapy. Am J Nephrol 43(6):397\u2013407","journal-title":"Am J Nephrol"},{"issue":"5","key":"705_CR98","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1097\/SLA.0b013e3181a3e562","volume":"249","author":"O Nafidi","year":"2009","unstructured":"Nafidi O et al (2009) Mechanisms of renal phosphate loss in liver resection-associated hypophosphatemia. Ann Surg 249(5):824\u2013827","journal-title":"Ann Surg"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-020-00705-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-020-00705-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T01:18:58Z","timestamp":1722993538000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-020-00705-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1007\/s00223-020-00705-3","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Diana Athonvarangkul\u00a0declares that she has no conflict of interest. Karl L. Insogna\u00a0has received grants from and been a consultant for Ultragenyx Pharmaceutical.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}